88 citations
,
August 2019 in “Frontiers in immunology” Tyrosine kinases are important in skin autoimmune diseases and could be targets for new treatments.
September 2014 in “SciBX” JAK inhibitors may help treat alopecia areata and promote hair regrowth.
52 citations
,
December 2014 in “Journal of Dermatological Science” Apremilast may help treat hair loss in alopecia areata.
11 citations
,
August 2021 in “Stem Cell Research & Therapy” Pimecrolimus reduces the effectiveness of stem cell therapy for atopic dermatitis.
7 citations
,
August 2023 in “Journal of the American Academy of Dermatology” JAK inhibitors offer new hope for treating severe alopecia areata.
May 2025 in “Orphanet Journal of Rare Diseases” TNF-α blockers and IL inhibitors improve symptoms in most patients with severe scalp condition, but more research is needed.
19 citations
,
August 2023 in “Journal of Dermatological Treatment” Abrocitinib may effectively treat stubborn alopecia universalis.
Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.
January 2026 in “Journal of Investigative Dermatology” 3D imaging effectively tracks skin changes in vitiligo treatment.
7 citations
,
April 2021 in “British Journal of Dermatology” Topical tofacitinib may effectively and safely regrow facial hair in some people with alopecia areata.
May 2025 in “International Journal of Trichology” Topical tofacitinib may help regrow hair in children with alopecia totalis.
1 citations
,
January 2026 in “Dermatology Reports” Tildrakizumab may cause alopecia areata, but stopping it and using corticosteroids can regrow hair.
12 citations
,
December 2022 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” New oral treatments for adult hair loss show promise, especially JAK inhibitors, with mild side effects.
August 2025 in “JEADV Clinical Practice” Dupilumab successfully treated a woman's alopecia areata and bullous pemphigoid, leading to full hair regrowth and symptom resolution.
5 citations
,
April 2025 in “Journal of Cosmetic Dermatology” Janus kinase inhibitors are effective and safe for treating Alopecia Areata.
9 citations
,
June 2013 in “Australasian Journal of Dermatology” Infliximab improved skin and bowel symptoms in Crohn's disease but caused side effects and the disease returned after stopping treatment.
3 citations
,
July 2025 in “Clinical and Experimental Dermatology” Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
July 2025 in “Journal of Investigative Dermatology” TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.
11 citations
,
December 2018 in “Journal of the European Academy of Dermatology and Venereology” Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.
July 2022 in “International Journal of Trichology” Tofacitinib helped an 8-year-old child recover from a type of hair loss that is hard to treat.
78 citations
,
March 2017 in “JAMA Dermatology” Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.
1 citations
,
September 2023 in “Rheumatology advances in practice” A woman's rare scalp condition worsened after using a specific arthritis medication, suggesting such medications can sometimes trigger or aggravate psoriasis.
1 citations
,
April 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” Oral tofacitinib significantly improves lichen planopilaris symptoms without adverse effects.
December 2023 in “Acta dermato-venereologica” Tofacitinib is effective for treating alopecia areata, and starting treatment early may improve results.
2 citations
,
November 2023 in “Acta dermato-venereologica” Tofacitinib is effective and safe for treating alopecia areata with a good drug survival rate.
January 2023 in “National Journal of Physiology, Pharmacy and Pharmacology” Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.
51 citations
,
June 2016 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.
25 citations
,
November 2022 in “British journal of dermatology/British journal of dermatology, Supplement” Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
November 2023 in “Journal of Cosmetic Dermatology” Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.
June 2025 in “Patient Preference and Adherence” Chinese patients with alopecia areata value JAK inhibitors but worry about side effects and relapse, highlighting the need for education and support.